The global cancer microbiome sequencing market size was valued at USD 384.25 million in 2025 and is projected to grow from USD 460.79 million in 2026 to USD 1970.78 million by 2034, registering a CAGR of 19.92% during the forecast period from 2026 to 2034. North America dominated the cancer microbiome sequencing market with a market share of 42.6% in 2025.
Cancer microbiome sequencing involves analyzing the genetic material of microorganisms found in or around tumors to understand their role in cancer development, progression, and treatment response. It uses advanced sequencing technologies to identify and characterize bacteria, fungi, viruses, and other microbes associated with cancer. This approach supports research into cancer biomarkers, personalized therapies, treatment resistance, and the interactions between the microbiome, tumors, and the immune system.
Download a Free Sample To learn more about this report,
Growing Use of Sequencing to Identify Microbiome-Based Cancer Biomarkers
The cancer microbiome sequencing market is advancing as researchers increasingly use 16S rRNA sequencing, shotgun metagenomic sequencing, and other next-generation sequencing approaches to identify microbial signatures associated with cancer development, progression, and treatment response. Sequencing is helping researchers examine microbial communities in tumor tissue and biological samples, supporting the discovery of potential biomarkers and improving understanding of host–microbiome interactions. This trend is supporting the cancer microbiome sequencing market size as precision oncology research increasingly incorporates microbiome data.
In June 2026, EMBL-led researchers reported a large-scale study identifying a robust gut microbiome signature associated with colorectal cancer. The analysis found microbiome patterns that remained consistent across different populations, sequencing methods, and age groups, strengthening the potential use of microbiome sequencing for cancer biomarker discovery.
Increasing Focus on Improving Accuracy and Reproducibility of Cancer Microbiome Sequencing
Another important trend is the growing emphasis on sequencing accuracy, contamination control, standardized analytical methods, and reproducibility. Cancer microbiome research faces challenges because microbial signals in tumor samples can be extremely low, making reliable detection difficult. Researchers are therefore developing improved sequencing and computational approaches to distinguish genuine tumor-associated microbial signals from technical contamination. This focus is supporting cancer microbiome sequencing market growth by improving confidence in sequencing-derived biomarkers and research findings.
In September 2025, Johns Hopkins Medicine researchers published findings from an extensive cancer sequencing study that detected substantially fewer microbial DNA sequences in human cancer samples than some earlier studies had reported. The findings highlighted the importance of rigorous sequencing methods and contamination controls for reliable cancer microbiome research.
Growing Research Interest in Microbiome-Based Cancer Detection
Growing evidence linking microbial communities with cancer development, progression, and treatment response is increasing interest in sequencing-based microbiome analysis. Shotgun metagenomics, 16S rRNA sequencing, and other sequencing approaches allow researchers to characterize microbial composition and identify microbial signatures associated with specific cancers. This is strengthening cancer microbiome sequencing market demand as researchers explore microbiome-based biomarkers for earlier detection and patient stratification. The availability of larger clinical datasets is also improving the ability to compare microbial patterns across populations and cancer types.
In July 2026, researchers published a population-based study using shotgun sequencing of microbiomes from 1,034 FIT-positive colorectal cancer screening participants to investigate microbial signatures associated with colorectal lesions.
High Complexity of Low-Abundance Microbiome Detection
Cancer-associated microbiomes can contain microorganisms at very low abundance, making accurate detection difficult and increasing the risk of contamination or false-positive findings. Differences in sample collection, DNA extraction, sequencing platforms, bioinformatics pipelines, and analytical methods can also produce inconsistent results between studies. These limitations remain important in cancer microbiome sequencing market analysis because researchers need highly sensitive and reproducible methods before microbiome signatures can be confidently translated into clinical applications. Standardization across laboratories and study populations remains necessary to improve comparability and reliability.
In April 2026, researchers published PRISM, a computational approach designed to improve microorganism identification and remove spurious signals from low-biomass cancer sequencing data, demonstrating the continuing need for improved analytical methods.
Expansion of Microbiome-Based Biomarkers and Precision Oncology
The growing ability to connect microbial composition with cancer biology is creating opportunities for sequencing technologies in early detection, patient stratification, treatment-response prediction, and precision oncology. Researchers are increasingly combining microbiome sequencing with genomic, transcriptomic, metabolomic, and clinical datasets to obtain a more complete understanding of tumor–microbe interactions. These cancer microbiome sequencing market trends could support development of non-invasive biomarker tests and personalized treatment strategies. Continued improvements in sequencing depth, bioinformatics, and multi-omics analysis are expected to expand the potential applications of cancer microbiome profiling.
In May 2026, researchers reported a circulating microbiome-DNA liquid biopsy approach for early gastric cancer detection, demonstrating the potential of microbial genetic signatures as non-invasive cancer biomarkers.
Translating Sequencing Findings into Reliable Clinical Applications
A major challenge is converting research-stage microbiome signatures into reproducible clinical tools that work across different populations, sample types, sequencing platforms, and healthcare settings. Microbial communities can vary according to diet, geography, medication, age, lifestyle, and other factors, making it difficult to establish universal biomarkers. Researchers therefore need larger prospective cohorts, standardized sequencing protocols, robust computational validation, and clinical studies before microbiome sequencing can become routinely useful in cancer care. This remains a critical consideration for the cancer microbiome sequencing market report as the field moves from exploratory research toward clinical implementation.
In June 2026, a large meta-analysis combining 6,779 samples from 27 studies found colorectal cancer microbiome signatures that were robust across different studies and sequencing approaches, illustrating progress toward more reproducible microbiome biomarkers.
Product Segment Dominated the Market with 64.7% Share in 2025
The product segment dominated the global cancer microbiome sequencing market with a 64.7% market share in 2025, valued at USD 0.25 billion. Its leadership is supported by the growing use of sequencing kits, assays, software, and other laboratory products required to characterize microbial communities associated with cancer research. Increasing adoption of sequencing-based approaches in microbiome studies is encouraging researchers to use integrated product portfolios for sample preparation, sequencing, analysis, and interpretation.
Service offerings continue to support laboratories and research organizations that require specialized sequencing, bioinformatics, data analysis, and workflow support. As microbiome studies become more complex, demand for external expertise and scalable sequencing services is expanding across research and clinical-development environments.
Request Customizationto receive a tailored report.
Translational Research and Diagnostics Segment Dominated the Market with 100% Share in 2025
The translational research and diagnostics segment accounted for a 100% share of the global cancer microbiome sequencing market in 2025, valued at USD 0.38 billion. Within this broader application area, colorectal cancer represents the largest specific cancer-type segment. Growing research into interactions between microbial communities, tumor biology, immune responses, and treatment outcomes is supporting the use of microbiome sequencing in cancer-related research and diagnostic development.
Colorectal, cervical, oral, and other cancer types continue to represent important areas of investigation. Researchers are examining how microbiome profiles may contribute to disease understanding, biomarker discovery, treatment response assessment, and the development of more personalized approaches to cancer research.
Next-Generation Sequencing Segment Dominated the Market with 72.8% Share in 2025
The next-generation sequencing segment dominated the global cancer microbiome sequencing market with a 72.8% market share in 2025, valued at USD 0.28 billion. NGS enables researchers to analyze microbial genetic material at scale, making it valuable for characterizing complex microbial communities associated with tumors and surrounding biological environments. Its ability to generate large volumes of sequencing data supports detailed microbiome profiling and comparative research.
Polymerase chain reaction remains an important technology for targeted microbial detection and validation. Within NGS, sequencing by synthesis, sequencing by ligation, and other approaches continue to address different research requirements based on workflow design, sequencing performance, and analytical objectives.
Pharmaceutical and Biotechnology Companies Segment is Projected to Register the Fastest Growth at a CAGR of 19.65%
The pharmaceutical and biotechnology companies segment is projected to register the fastest growth at a CAGR of 19.65% during the forecast period. Increasing interest in the microbiome's potential role in cancer biology is encouraging drug developers and biotechnology companies to investigate microbial biomarkers, therapeutic targets, treatment response, and microbiome-based interventions. Sequencing technologies provide researchers with tools to characterize microbial communities and generate data that can support drug-development programs.
Academic and research institutes remain important users of cancer microbiome sequencing for basic and translational studies. Hospitals and diagnostic laboratories are also exploring sequencing-based approaches as research progresses toward clinically relevant biomarkers, diagnostic applications, and more personalized cancer-management strategies.
Speak to an Analystto discuss market opportunities.
North America's cancer microbiome sequencing market accounted for 42.6% of the global market, reaching USD 0.16 billion in 2025, and is projected to grow at a CAGR of 17.85% during the forecast period. The region's leading position is supported by advanced genomic research infrastructure, increasing cancer research activities, growing adoption of next-generation sequencing technologies, and rising investments in precision medicine and microbiome-based cancer research.
The United States represents a major market in North America. Its advanced genomics and cancer research ecosystem, strong biotechnology sector, and increasing focus on precision oncology continue to support demand for cancer microbiome sequencing technologies.
Canada's established biomedical research infrastructure, expanding genomics capabilities, and increasing research into the relationship between the microbiome and cancer continue to support market development.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cancer microbiome sequencing market accounted for 19.8% of the global market, reaching USD 0.08 billion in 2025, and is projected to grow at a CAGR of 21.65% during the forecast period. The region records the fastest growth among the listed markets, supported by expanding genomic research capabilities, increasing cancer incidence, growing investments in biotechnology, and rising adoption of next-generation sequencing and precision medicine technologies.
China represents a major market within the Asia Pacific. Expanding cancer research programs, growing genomics capabilities, increasing biotechnology investments, and rising adoption of sequencing technologies continue to drive market development.
Japan's advanced healthcare and life sciences infrastructure, strong cancer research capabilities, and increasing focus on precision medicine and molecular diagnostics continue to support market growth.
India's expanding biotechnology sector, increasing cancer research activities, growing genomics capabilities, and rising investments in advanced sequencing technologies continue to create opportunities for cancer microbiome sequencing market development.
Europe's cancer microbiome sequencing market accounted for 27.4% of the global market, reaching USD 0.11 billion in 2025, and is expected to register a CAGR of 17.25% during the forecast period. Growing investments in cancer genomics, increasing research into tumor microbiomes, expanding precision medicine initiatives, and rising adoption of advanced sequencing technologies continue to support regional market growth.
Germany represents a major European market. Its strong biomedical research infrastructure, expanding cancer genomics activities, and increasing investments in precision medicine continue to support cancer microbiome sequencing research and applications.
The United Kingdom's established genomics research ecosystem, growing cancer research activities, and increasing focus on personalized oncology continue to create opportunities for cancer microbiome sequencing technologies.
Latin America's cancer microbiome sequencing market accounted for 6.1% of the global market, reaching USD 0.02 billion in 2025, and is expected to grow at a CAGR of 18.15% during the forecast period. Increasing cancer research, gradual expansion of genomic testing infrastructure, growing biotechnology activities, and rising awareness of precision medicine continue to support regional market growth.
Brazil represents a major regional market. Its expanding biomedical research sector, increasing cancer research activities, and growing adoption of genomic technologies continue to create opportunities for cancer microbiome sequencing.
The Middle East & Africa cancer microbiome sequencing market accounted for 4.1% of the global market, reaching USD 0.02 billion in 2025, and is anticipated to grow at a CAGR of 16.95% during the forecast period. Increasing investments in healthcare and biotechnology, growing cancer research activities, and gradual development of genomic testing infrastructure continue to support regional market development.
The UAE's investments in advanced healthcare, genomics, biotechnology, and precision medicine continue to support the adoption of advanced sequencing technologies for cancer research.
Saudi Arabia's expanding healthcare infrastructure, growing investments in genomics and biotechnology, and increasing focus on advanced cancer research continue to strengthen opportunities for cancer microbiome sequencing technologies.
The global cancer microbiome sequencing market is highly competitive, with leading genomics, sequencing, molecular diagnostics, and microbiome technology companies competing through next-generation sequencing (NGS), metagenomic analysis, microbial profiling, bioinformatics, and precision oncology solutions. The major players in the market include Novogene Corporation, Psomagen, PerkinElmer Genomics, Illumina, Thermo Fisher Scientific, Viome, Invivo Diagnostics, Zymo Research Corp., Metabiomics, and others.
Industry participants are focusing on developing advanced sequencing and bioinformatics technologies for characterizing tumor-associated microbiota and identifying microbial signatures associated with cancer development, diagnosis, prognosis, and treatment response. Companies are investing in whole-genome sequencing, 16S rRNA sequencing, shotgun metagenomics, RNA sequencing, spatial analysis, and AI-enabled bioinformatics to improve the identification of complex interactions between cancer cells and the tumor microbiome. Growing interest in precision oncology, biomarker discovery, immunotherapy response prediction, and non-invasive cancer diagnostics is also encouraging companies to expand microbiome sequencing capabilities and research collaborations.
Illumina is a leading genomics technology company providing next-generation sequencing platforms, consumables, and informatics solutions used extensively in cancer genomics and microbiome research. Its sequencing technologies enable researchers to analyze microbial communities and characterize genetic and molecular changes associated with cancer, supporting applications ranging from biomarker discovery to translational research.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
LAMEA Tangential Flow Filtration Market Size Analysis and Forecast 2034
North America TB Diagnostics Market Size & Trends Analysis by 2034
Europe TB Diagnostics Market Growth Trends and Competitive Analysis 2034
Bioinformatics Services Market Size, Share, Growth, Analysis, 2034
North America Tangential Flow Filtration Market Size, Share and Forecast to 2034
Asia Pacific Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2033
We are featured on:
sales@straitsresearch.com